Edition:
India

Synlogic Inc (SYBX.OQ)

SYBX.OQ on NASDAQ Stock Exchange Global Market

10.27USD
2:29am IST
Change (% chg)

$0.32 (+3.22%)
Prev Close
$9.95
Open
$10.00
Day's High
$10.45
Day's Low
$9.97
Volume
50,376
Avg. Vol
5,970
52-wk High
$23.00
52-wk Low
$8.83

Latest Key Developments (Source: Significant Developments)

Synlogic, Ginkgo Bioworks To Collaborate To Discover New Living Medicines To Treat Neurological And Liver Disorders
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Synlogic Inc ::SYNLOGIC INC - CO, ORGANISM COMPANY GINKGO BIOWORKS TO COLLABORATE TO DISCOVER NEW LIVING MEDICINES TO TREAT NEUROLOGICAL AND LIVER DISORDERS.  Full Article

Synlogic qtrly loss per share $1.66‍​
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Synlogic Inc ::Synlogic reports third quarter 2017 financial results and recent progress.Q3 revenue $100,000.Synlogic Inc - qtrly loss per share $1.66‍​.  Full Article

Synlogic says ‍SYNB1020 was safe, well tolerated in subjects
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Synlogic Inc :Synlogic reports positive top-line phase 1 data demonstrating safety and tolerability and proof of mechanism in healthy volunteers for synb1020, a synthetic biotictm medicine for the treatment of hyperammonemia.Synlogic inc - ‍data support initiation of two phase 1b/2a studies in 2018​.Synlogic - ‍synb1020 was safe, well tolerated in subjects in multiple ascending dose cohorts.Synlogic - ‍there have been no serious adverse events, no cases of infection with bacteria in synb1020 study ​.  Full Article

Synlogic says co entered into sales agreement with Cowen And Company, LLC ​
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Synlogic Inc :Synlogic Inc - ‍on October 13, 2017 co entered into a sales agreement with Cowen And Company, LLC - SEC filing ​.Synlogic Inc - pursuant to agreement co may offer and sell, shares of its common stock, par value $0.001 per share having an offering price of up to $50 million.  Full Article

Mirna therapeutics' investigational new drug for MRX34 has been placed on full clinical hold
Friday, 30 Sep 2016 

Mirna Therapeutics Inc : Investigational new drug for MRX34, investigational Microrna Therapy for multiple cancers, has been placed on full clinical hold .Anticipates that it will receive a formal clinical hold letter from FDA within 30 days - SEC filing.  Full Article

Mirna Therapeutics qtrly net loss attributable to common stockholders $5.64 mln
Monday, 15 Aug 2016 

Mirna Therapeutics Inc : Mirna therapeutics reports second quarter 2016 financial results and program updates . Qtrly net loss attributable to common stockholders $5.64 million versus $7.23 million .Expects that current cash resources will be sufficient to meet operating requirements into 2018.  Full Article

Mirna Therapeutics reports Q1 net loss of about $6.6 million
Friday, 13 May 2016 

Mirna Therapeutics Inc :Says net loss was approximately $6.6 million for Q1 of 2016 compared to $4.3 million in comparable period in 2015.  Full Article